article thumbnail

77% of researchers not using alternatives to animal testing

Drug Discovery World

New survey findings have revealed that 77% of R&D professionals are not using in vitro cell-based alternatives to animal testing, and only 23% describe themselves as ‘very familiar’ with any kind of animal model alternative. This comes despite new laws, such as the FDA Modernization Act 2.0

article thumbnail

Kidney-tissue platforms could reduce animal testing in toxicology studies

Drug Discovery World

Kidney disease researchers at the University of Washington will use a multimillion-dollar federal grant to advance drug development platforms that would reduce reliance on animal tests. The FDA Modernization Act 2.0 The investigators, in the UW schools of Medicine and Pharmacy, received the $7.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Low endotoxin biomaterials could help to reduce animal testing

Drug Discovery World

This can improve the validity of 3D in vitro models and help to reduce animal testing.” The post Low endotoxin biomaterials could help to reduce animal testing appeared first on Drug Discovery World (DDW).

article thumbnail

FDA expands organ-on-a-chip research collaboration

Drug Discovery World

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System. . Changes to rules for animal testing . Recreating the in vitro structure of tissues.

FDA 130
article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

FDA Law Blog: Drug Discovery

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. adequate to justify the proposed clinical testing.”

article thumbnail

Podcast: The FDA Modernisation Act 2.0 and seizure liability testing

Drug Discovery World

It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 The post Podcast: The FDA Modernisation Act 2.0 and seizure liability testing appeared first on Drug Discovery World (DDW).

FDA 130
article thumbnail

How does the FDA Modernisation Act 2.0 impact seizure liability testing in drug discovery?

Drug Discovery World

The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 The post How does the FDA Modernisation Act 2.0

FDA 130